Decursin

Decursin ((+) -Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities[1][2][3][4].

Product Specifications

CAS Number

[5928-25-6]

Product Name Alternative

(+) -Decursin

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Apoptosis; CXCR; PKC

Type

Natural Products

Related Pathways

Apoptosis; Epigenetics; GPCR/G Protein; Immunology/Inflammation; TGF-beta/Smad

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Decursin.html

Purity

99.92

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

C/C(C)=C\C(O[C@H](C(C)(C)O1)CC2=C1C=C(O3)C(C=CC3=O)=C2)=O

Molecular Formula

C19H20O5

Molecular Weight

328.36

Precautions

H302, H315, H319

References & Citations

[1]Yim D, et al. A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells. Cancer Res. 2005 Feb 1;65 (3) :1035-44.|[2]Jung SY, et al. Decursin inhibits vasculogenesis in early tumor progression by suppression of endothelial progenitor cell differentiation and function. J Cell Biochem. 2012 May;113 (5) :1478-87. |[3]Son DB, et al. Decursin Alleviates Mechanical Allodynia in a Paclitaxel-Induced Neuropathic Pain Mouse Model. Cells. 2021 Mar 4;10 (3) :547.|[4]Ahn KS, et al. Decursin: a cytotoxic agent and protein kinase C activator from the root of Angelica gigas. Planta Med. 1996 Feb;62 (1) :7-9.